Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib Monotherapy or Combination Therapy in Previously Untreated Advanced/Metastatic NSCLC with KRAS G12C Mutation
NCT05789082Phase 2Recruiting
- Sponsor
- Roche
- Start
- Jun 2023
- Primary completion
- Jan 2032
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 2 trial of divarasib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Jun 2023; status: recruiting.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05789082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789082.